Meeting
2014 ASCO Annual Meeting
Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Scott T. Tagawa
Weill Cornell Medical College, New York, NY
Scott T. Tagawa , Edwin M. Posadas , Justine Yang Bruce , Emerson A. Lim , Daniel Peter Petrylak , Weimin Peng , Raymond Scott Maul , Hans W. Smit , Namphuong Tran , David M. Nanus
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01400555
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 5025)
DOI
10.1200/jco.2014.32.15_suppl.5025
Abstract #
5025
Poster Bd #
40
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: W. Kevin Kelly
Poster
2020 Genitourinary Cancers Symposium
Randomized phase II study of docetaxel (D) + abiraterone acetate (AA) versus D after disease progression to first-line AA in metastatic castration-resistant prostate cancer (mCRPC): ABIDO-SOGUG Trial.
First Author: Miguel Angel Climent Duran
Poster
2015 Genitourinary Cancers Symposium
Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Alice Clement-Zhao
Poster
2014 ASCO Annual Meeting
Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone acetate (Abi).
First Author: Fred Saad